SB-408124
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.164.461 |
Chemical and physical data | |
Formula | C19H18F2N4O |
Molar mass | 356.377 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
SB-408124 is a drug which is a non-peptide antagonist selective for the orexin receptor subtype OX1, with around 70x selectivity for OX1 over OX2 receptors, and improved oral bioavailability compared to the older OX1 antagonist SB-334867. It is used in scientific research into the function of orexinergic neurons in the body.[1][2]
References
[edit]- ^ Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ (January 2004). "Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor". British Journal of Pharmacology. 141 (2): 340–6. doi:10.1038/sj.bjp.0705610. PMC 1574197. PMID 14691055.
- ^ Peng HY, Chang HM, Chang SY, Tung KC, Lee SD, Chou D, et al. (July 2008). "Orexin-A modulates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit". American Journal of Physiology. Endocrinology and Metabolism. 295 (1): E117-29. doi:10.1152/ajpendo.90243.2008. PMID 18477704. S2CID 587272.